Alnylam Pharma (ALNY) Tops Q3 EPS by 8c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $288.18 +0.62%
Revenue Growth %: +70.6%
Financial Fact:
Net loss: -90.13M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: +70.6%
Financial Fact:
Net loss: -90.13M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($1.58), $0.08 better than the analyst estimate of ($1.66). Revenue for the quarter came in at $125.9 million versus the consensus estimate of $120.75 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Nike names former Pfizer CFO David Denton as new finance chief
- FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
